Frequency Therapeutics, Inc. (FREQ)

NASDAQ: FREQ · IEX Real-Time Price · USD
1.79
-0.11 (-5.79%)
Sep 30, 2022 4:00 PM EDT - Market closed
-5.79%
Market Cap 63.12M
Revenue (ttm) n/a
Net Income (ttm) -91.33M
Shares Out 35.26M
EPS (ttm) -2.54
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 57,025
Open 1.82
Previous Close 1.90
Day's Range 1.79 - 1.89
52-Week Range 1.00 - 7.88
Beta 0.74
Analysts Buy
Price Target 8.16 (+355.9%)
Earnings Date Nov 14, 2022

About FREQ

Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules and activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, i... [Read more...]

Industry Biotechnology
IPO Date Oct 3, 2019
Employees 72
Stock Exchange NASDAQ
Ticker Symbol FREQ
Full Company Profile

Financial Performance

In 2021, FREQ's revenue was $14.07 million, a decrease of -61.96% compared to the previous year's $36.98 million. Losses were -$84.69 million, 219.4% more than in 2020.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for FREQ stock is "Buy." The 12-month stock price forecast is 8.16, which is an increase of 355.87% from the latest price.

Price Target
$8.16
(355.87% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Frequency Therapeutics to Participate in September Investor and Medical Conferences

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate potential ...

1 month ago - Business Wire

Frequency Therapeutics Provides Business Updates and Second Quarter 2022 Financial Results

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate potential ...

1 month ago - Business Wire

Frequency Therapeutics, Inc. (FREQ) Upgraded to Buy: What Does It Mean for the Stock?

Frequency Therapeutics, Inc. (FREQ) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

4 months ago - Zacks Investment Research

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Frequency Therapeutics, Inc.

Wilmington, Delaware--(Newsfile Corp. - May 18, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Frequency Therapeutics, Inc. (NasdaqGS: FREQ) on behal...

4 months ago - Newsfile Corp

Frequency Therapeutics to Participate in 2022 H.C. Wainwright Global Investment Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate regenerati...

4 months ago - Business Wire

Frequency Therapeutics Provides Business Updates and First Quarter 2022 Financial Results

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate regenerati...

4 months ago - Business Wire

Frequency Therapeutics to Participate in B. Riley Securities' Neuro & Ophthalmology Investor Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate regenerati...

5 months ago - Business Wire

Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2021 Financial Results

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate regenerati...

6 months ago - Business Wire

Frequency Therapeutics to Participate in Upcoming March 2022 Investor Conferences

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate regenerati...

7 months ago - Business Wire

Frequency Therapeutics to Present 2022 Business and Pipeline Overview at the 40th Annual J.P. Morgan Healthcare Confe...

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate regenerati...

8 months ago - Business Wire

Frequency Therapeutics' Hearing Loss Candidate Shows Improved Speech Perception In Noise

Frequency Therapeutics Inc (NASDAQ: FREQ) shared the results from its FX-322-113 study of FX-322 in severe sensorineural hearing loss (SNHL). The Phase 1b study, FX-322, was associated with a hearing si...

9 months ago - Benzinga

Frequency Therapeutics Shares Results from FX-322-113 Severe Sensorineural Hearing Loss Study Showing Speech Percepti...

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate regenerati...

9 months ago - Business Wire

Frequency Therapeutics, Inc. (FREQ) Reports Q3 Loss, Lags Revenue Estimates

Frequency Therapeutics, Inc. (FREQ) delivered earnings and revenue surprises of -32.73% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for...

10 months ago - Zacks Investment Research

Frequency Therapeutics Provides Business Updates and Third Quarter 2021 Financial Results

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate regenerati...

10 months ago - Business Wire

Frequency Therapeutics redesigns study after disappointing Phase 2 results, debuts new hearing loss and MS drugs

In Frequency Therapeutics' short lifetime as a company, it's had its ups and downs. On Tuesday, during an R&D event day, the company unleashed a slew of announcements that add context to the development...

10 months ago - TechCrunch

Frequency Therapeutics Holds Virtual R&D Event Highlighting Clinical Advancement of FX-322, a New Potential Restorati...

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate regenerati...

10 months ago - Business Wire

Analysts Estimate Frequency Therapeutics, Inc. (FREQ) to Report a Decline in Earnings: What to Look Out for

Frequency Therapeutics, Inc. (FREQ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

10 months ago - Zacks Investment Research

Frequency Therapeutics Virtual R&D Event to Detail FX-322 Clinical Advances, a New Program for Hearing Restoration an...

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate regenerati...

11 months ago - Business Wire

Frequency Therapeutics Announces First Subject Dosed in FX-322 Phase 2b Acquired Sensorineural Hearing Loss (SNHL) St...

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate regenerati...

11 months ago - Business Wire

Frequency Therapeutics' New Data Of Hearing Loss Candidate Fails To Impress Investors

Frequency Therapeutics Inc (NASDAQ: FREQ) has announced that four additional sensorineural hearing loss (SNHL) subjects from its FX-322-111 open-label study achieved statistically significant hearing im...

1 year ago - Benzinga

Frequency Therapeutics Announces New FX-322 Results Showing That Additional Study Participants Gain Hearing Improveme...

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate regenerati...

1 year ago - Business Wire

Frequency Therapeutics to Present at Upcoming Investor Conferences

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused ...

1 year ago - Business Wire

Moore Kuehn, PLLC Encourages Investors of FREQ to Contact Law Firm

New York, New York--(Newsfile Corp. - August 12, 2021) -  Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating potential claims involving directors and officers regarding po...

1 year ago - Newsfile Corp

Frequency Therapeutics, Inc. (FREQ) Reports Q2 Loss, Tops Revenue Estimates

Frequency Therapeutics, Inc. (FREQ) delivered earnings and revenue surprises of -1.96% and 26.49%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Frequency Therapeutics Provides Business Updates and Second Quarter 2021 Financial Results

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused ...

1 year ago - Business Wire